Antibiotics are drugs that either kill or slow the growth of bacteria. Under selective pressure, microbes can acquire drug resistance and these pathogenic strains pose a growing public health threat. Therefore, the Seeker desires novel methods to combat antibiotic resistance, particularly in Gram-negative bacteria.
This is a Reduction-to-Practice Challenge that requires written documentation and experimental proof-of-concept data.
Antibiotic-resistant Gram-negative infections have emerged as major concerns in hospitals, nursing homes, and other healthcare settings. To blunt the profound impact on patients and mitigate the rising costs of treating these infections, novel approaches, targets, and mechanisms are urgently needed. Therefore, the Seeker desires proposals that will reveal novel mechanisms and targets to launch drug discovery programs targeting multidrug resistant Gram-negatives. Additionally, the Seeker desires proposals addressing insights into the factors limiting small molecule uptake and retention in Gram-negatives (“permeability and efflux”).
Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on December 2, 2019.
About the Seeker
For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world – including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola.